The domestic antibacterial drug market has entered the market again, and it is predicted that the next 8 years may show a trend of first rising and then falling

【Pharmaceutical Network Market Analysis】 In the field of steady growth of antibacterial drugs, the author learned that a pharmaceutical company has recently ushered in
.

That is, on August 30, Haizheng Pharmaceutical issued an announcement that it had recently received the "Notice of Approval of the Marketing Application for Chemical API"
for the Posaconazole API approved and issued by the State Food and Drug Administration.

Up to now, the company has invested about 23.
35 million yuan
in the drug research and development project.

According to the data, posaconazole is the second generation of triazole antifungal drugs approved for marketing by the US Food and Drug Administration in 2006, which was developed by Merck and has global sales of more than $
300 million in 2020.

It is itself a triazole antifungal drug, which can inhibit the synthesis of fungal cell membranes, thereby producing antifungal effects, can be used to prevent invasive Aspergillus and Candida infection, suitable for the prevention of 13 years of age and older due to severe immunodeficiency, resulting in an increased risk of acute Aspergillus and Candida infection
.

At present, the main domestic manufacturers of Posaconazole APIs are Zhejiang Aoxiang Pharmaceutical Co.
, Ltd.
and Shandong Jincheng Kunlun Pharmaceutical Co.
, Ltd
.

It is understood that in recent years, the amount of antibacterial drugs used throughout the body in China has shown an overall upward trend, from 2016 to 2019, from 159.
998 billion yuan to 169.
781 billion yuan, with an annual compound growth rate of 2.
86%.


In 2021, it was 130.
217 billion yuan
.

It is estimated that in 2022, the market size of China's systemic antibacterial drugs will reach 146.
851 billion yuan
.

With the implementation of the policy, the use of general broad-spectrum antibiotics will continue to be controlled, patients with drug-resistant bacteria infections will have more timely access to targeted drugs, and the use of antibacterial drugs in China will undergo structural adjustments
.

In the field of antimicrobials, there are few
enterprises and pipelines in research.

However, the industry said that in the field of antibacterial drugs, there are few enterprises and pipelines in research, but the "blank blue ocean zone" suitable for differentiated layout is more likely to emerge explosive drugs
.

For example, as a "best in class" antibacterial drug, contezolid brings new solutions
.

The success of contezolid marks a comprehensive upgrade of Mengke Pharmaceutical in the field of antibacterial drugs, and the multi-year layout is gradually entering a comprehensive harvest period
.

At the same time, the emergence of the drug has also made the domestic antibacterial drug field about to usher in changes
.

The data shows that in addition to the advantages of efficacy and safety, the drug also has the characteristics of few adverse reactions related to the interaction with other drugs, wide distribution in vivo, oral administration, low risk of drug resistance, and wide range of potential indications, and the market prospect is broad
.

At present, contezolid has entered the commercialization stage in China, and phase II clinical trials
in the United States have been completed.

For the future market prospects of domestic antimicrobials, Sullivan predicts that from 2022 to 2030, the market size of Antimicrobials in China will show a trend of first rising and then declining
.

Among them, the compound annual growth rate of market size in 2022-2025 is about 2.
1%, while the compound annual growth rate of 2025-2030 is -1.
9%.
In addition, analysts pointed out that compared with popular research and development areas such as tumors and chronic diseases, super antibacterial drugs have fewer
enterprises and pipeline layouts in research.

However, with the accelerated development of bacterial resistance in the clinic, super antimicrobials have become a blue ocean field
that has attracted much attention.

Among them, among the "super antibiotics" of the oxazolidinone class, three drugs have been approved for marketing in China, namely linezolid, terdezolid and contezolid
.

It is predicted that with the clear hierarchical management of China's antimicrobial market and the higher safety of oxazolidinone antibacterial drugs will be listed in China, by 2030, the market size of China's oxazolidinone antibacterial drugs will grow to 6 billion yuan
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.